Laura M. Walker

Laura M. Walker

Auto-generated profile, based on publicly available information

Laura M. Walker

Invivyd Inc., Waltham, MA 02451, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2020 in Science
Verified
Journal Article
Open access
PDF file
AWAnna Z. Wec
Anna Z. Wec
DWDaniel Wrapp
Daniel Wrapp
AHAndrew S. Herbert
Andrew S. Herbert
DMDaniel P. Maurer
Daniel P. Maurer
DHDenise Haslwanter
Denise Haslwanter
LWLaura M. Walker
Laura M. Walker
Seeking broad protection: As scientists develop therapeutic antibodies and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the risk of emergent coronaviruses makes it important to also identify broadly protective antibodies. Wec et al. isolated and characterized hundreds of antibodies against the viral spike protein of SARS-CoV-2 from the memory B cells of a survivor of the 2003 outbreak caused by the related coronavirus, SARS-CoV. In both of these viruses, the spike protein facilitated viral entry by binding to the angiotensin-converting enzyme 2 (ACE2) receptor on human cells. The antibodies targeted multiple sites on the spike protein, but of nine antibodies that showed strong cross-neutralization, eight targeted the domain that binds to ACE2. These eight antibodies also neutralized a bat SARS-related virus. Illuminating the epitopes on the viral spike protein that bind cross-neutralizing antibodies could guide the design of broadly protective vaccines. Science , this issue p. 731

19 February 2021 in Science
Verified
Journal Article
Open access
PDF file
CRC. Garrett Rappazzo
C. Garrett Rappazzo
LTLong Ping Victor Tse
Long Ping Victor Tse
CKChengzi I. Kaku
Chengzi I. Kaku
DWDaniel Wrapp
Daniel Wrapp
MSMrunal Sakharkar
Mrunal Sakharkar
LWLaura M. Walker
Laura M. Walker
Targeting sarbecoviruses: As we continue to battle the COVID-19 pandemic, we must confront the possibility of new pathogenic coronaviruses emerging in humans in the future. With this in mind, Rappazzo et al. isolated antibodies from a survivor of the 2003 severe acute respiratory syndrome coronavirus (SARS-CoV), used yeast display libraries to introduce diversity into these antibodies, and then screened for binding to SARS-CoV-2. One of the affinity-matured progeny strongly neutralized SARS-CoV-2, SARS-CoV, and two SARS-related viruses from bats. In addition, this antibody bound to the receptor-binding domains from a panel of sarbecoviruses, suggesting broader activity, and provided protection against SARS-CoV and SARS-CoV-2 in mouse models. Science , this issue p. 823

30 January 2018 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
LWLaura M. Walker
Laura M. Walker
DBDennis R. Burton
Dennis R. Burton

23 December 2016 in Science Immunology
Verified
Journal Article
Closed access
PDF file
MGMorgan S. A. Gilman
Morgan S. A. Gilman
CCCarlos A. Castellanos
Carlos A. Castellanos
MCMan Chen
Man Chen
JNJoan O. Ngwuta
Joan O. Ngwuta
EGEileen Goodwin
Eileen Goodwin
LWLaura M. Walker
Laura M. Walker
Anti–RSV F antibody repertoire profiling reveals new opportunities for vaccine design and passive therapy.

4 March 2016 in Science
Verified
Journal Article
Closed access
PDF file
ZBZachary A. Bornholdt
Zachary A. Bornholdt
HTHannah L. Turner
Hannah L. Turner
CMCharles D. Murin
Charles D. Murin
WLWen Li
Wen Li
DSDevin Sok
Devin Sok
LWLaura M. Walker
Laura M. Walker
Profiling the antibody response to Ebola: The recent Ebola virus outbreak in West Africa illustrates the need not only for a vaccine but for potential therapies, too. One promising therapy is monoclonal antibodies that target Ebola's membrane-anchored glycoprotein (GP). Bornholdt et al. isolated and characterized 349 antibodies from a survivor of the 2014 outbreak. A large fraction showed some neutralizing activity and several were quite potent. Structural analysis revealed an important site of vulnerability on the membrane stalk region of GP. Antibodies targeting this area were therapeutically effective in Ebola virus–infected mice. Science , this issue p. 1078

12 February 2021 in Science Immunology
Verified
Journal Article
Open access
PDF file
MSMrunal Sakharkar
Mrunal Sakharkar
CRC. Garrett Rappazzo
C. Garrett Rappazzo
WWWendy F. Wieland-Alter
Wendy F. Wieland-Alter
CHChing-Lin Hsieh
Ching-Lin Hsieh
DWDaniel Wrapp
Daniel Wrapp
LWLaura M. Walker
Laura M. Walker
A comprehensive understanding of the kinetics and evolution of the human B cell response to SARS-CoV-2 infection will facilitate the development of next-generation vaccines and therapies. Here, we longitudinally profiled this response in mild and severe COVID-19 patients over a period of five months. Serum neutralizing antibody (nAb) responses waned rapidly but spike (S)-specific IgG + memory B cells (MBCs) remained stable or increased over time. Analysis of 1,213 monoclonal antibodies (mAbs) isolated from S-specific MBCs revealed a primarily de novo response that displayed increased somatic hypermutation, binding affinity, and neutralization potency over time, providing evidence for prolonged antibody affinity maturation. B cell immunodominance hierarchies were similar across donor repertoires and remained relatively stable as the immune response progressed. Cross-reactive B cell populations, likely re-called from prior endemic beta-coronavirus exposures, comprised a small but stable fraction of the repertoires and did not contribute to the neutralizing response. The neutralizing antibody response was dominated by public clonotypes that displayed significantly reduced activity against SARS-CoV-2 variants emerging in Brazil and South Africa that harbor mutations at positions 501, 484 and 417 in the S protein. Overall, the results provide insight into the dynamics, durability, and functional properties of the human B cell response to SARS-CoV-2 infection and have implications for the design of immunogens that preferentially stimulate protective B cell responses.